Low-expression of miR-7 promotes cell proliferation and exhibits prognostic value in osteosarcoma patients.

AIM: MicroRNAs (miRNAs) play important roles in occurrence and development of osteosarcoma. Previous studies had verified the role of microRNA-7 (miR-7) in various diseases, especially in cancers. Our purpose in this study was to investigate the values of miR-7 in development and prognosis of osteosarcoma. METHODS: QRT-PCR was used to measure the expression of miR-7 in osteosarcoma tissues, adjacent tissues and healthy tissues as well as in osteosarcoma cell lines MG63, U2OS and normal osteoblastic cell line hFOB1.19. CCK-8 and siRNA assays were performed to estimate the effect of miR-7 in the process of cell proliferation. The Kaplan-Meier and Cox regression analysis were performed to detect the prognostic values of the miR-7 in osteosarcoma patients. RESULTS: The results demonstrated that miR-7 expression decreased in osteosarcoma tissues and cell lines compared with the controls. Proliferation assay declared that the cell proliferation was accelerated by down-regulation of miR-7. Kaplan-Meier exhibited that the overall survival time of low-miR-7 expression was shorter than those with high-miR-7 expression (P=0.001). Cox regression analysis revealed that Enneking, distant metastasis and recurrence were all prognostic factors just like low-miR-7. CONCLUSION: The expression of miR-7 was lower in osteosarcoma tissues and cell lines and miR-7 acted as a tumor suppressor. The low-expression of miR-7 was associated with clinicopathologic characteristics (age, tumor site, Enneking, therapies). Moreover, miR-7 might be an independent prognostic marker and promote cell proliferation in osteosarcoma.

CD192 gene variant and susceptibility to cervical cancer: a meta analysis.

BACKGROUND: Several molecular epidemiological studies have explored the association between G46295A variant of CD192 gene and cervical cancer susceptibility in distinct populations. However, the results are contradictory. To provide convincing evidence for the association, we performed the present meta-analysis incorporating all case-control studies. METHODS AND FINDINGS: The Cochrane, Google Scholar and PubMed databases were systematically searched to identify the potentially relevant studies. Statistical analyses were performed using R software. Crude odds ratio (OR) was calculated to estimate the risk of cervical cancer. Five case-control studies were considered in the final analysis. Using the homozygous, heterogeneous, allele, dominant, and recessive model, we found the association between CD192 G46295A variant and cervical cancer was not statistically significant. CONCLUSIONS: This meta-analysis shows that the CD192 G46295A variant may not confer genetic susceptibility towards cervical cancer.

Efficacy of edaravone on coronary artery bypass patients with myocardial damage after ischemia and reperfusion: a meta analysis.

OBJECTIVES: To assess the efficacy and safety of edaravone for myocardial damage during myocardial ischemia and reperfusion (I/R). METHODS: We included randomized controlled trials that compared edaravone with placebo or no intervention in patients with acute myocardial infarction or undergoing coronary artery bypass. Two authors selected eligible trials, assessed trial quality and independently extracted the data. RESULTS: Seven clinical trials were eventually included and analyzed in this study, involving 148 participants. Four trials were defined as waiting assessment. All of the three remaining trials compared edaravone and another treatment combined with other treatment alone, used the same dose of edaravone injections (60 mg per day) and course of treatment (14 days), evaluated the effect of edaravone at different times, applied different methods, reported adverse events, and showed no differences between the treatment group and the control group. When pooling all of the trials in one dataset, edaravone appeared to decrease the proportion of participant with marked myocardial damage during I/R as compared with the control group. The meta-analysis also revealed decreased CK-MB, cTnI and MDA, and increased content of SOD. CONCLUSIONS: Due to the moderate risk of bias and small sample, our observation of an effective treatment trend of edaravone for I/R requires future larger, high-quality trials to confirm.

Minimally invasive video-assisted versus conventional open thyroidectomy on immune response: a meta analysis.

OBJECTIVES: The aim of this study was to compare the immune response between the minimally invasive video-assisted thyroidectomy (MIVAT) and conventional thyroidectomy (CT). METHODS: An exhaustive literature search was performed in the Medline, Embase, and Cochrane Library to identify the randomized controlled trials comparing the immune response between MIVAT and CT. Relevant data were extracted and statistical analysis was done using RevMan 5.0. RESULTS: Twelve trials including 389 patients were identified. Immune-competent cells demonstrated no significant differences between MIVAT and CT. The including trails were assessed various perioperative plasma cytokine concentrations with no significant differences in interleukin-6 (IL-6), T lymphocytes (CD4(+), CD8(+), CD4/CD8) and NK cells between the MIVAT and CT. However, meta-analysis showed lower counts on postoperative days at 72 h was showed lower C-reactive protein (CRP) level compared to the preoperation levels but showed no significant difference within 24 h in MIVAT S group compared with CT group. Tumor necrosis factor alpha (TNF-α) level after surgery within 24 h and 72 h showed lower TNF-α level after MIVAT surgery within 24 h and 72 h. CONCLUSIONS: This meta-analysis demonstrates that, MIVAT has less immune response outcomes and that it is a more ideal choice for the patients relative to the conventional surgery.

Decreased expression of a novel lncRNA CADM1-AS1 is associated with poor prognosis in patients with clear cell renal cell carcinomas.

The clear cell renal cell carcinoma (ccRCC) is the most common subtype in renal cell carcinomas. Rapidly accumulating studies show that the long non-coding RNAs (lncRNAs) may play essential roles in cancers. In this study, we investigated the expression pattern of a novel lncRNA CADM1-AS1 in ccRCC by quantitative real time PCR. The results showed that CADM1-AS1 expression was down-regulated in tumor tissues in 64 patients with ccRCC compared with adjacent non-tumor tissues. Furthermore, the expression of CADM1-AS1 was positively correlated with the expression of mRNA CADM1 in ccRCC specimens (R = 0.611, P <0.0001). Decreased CADM1-AS1 expression was correlated with the progression of AJCC stage (P = 0.039) and worse survival of ccRCC patients (P <0.05). Also, multivariate analysis identified low CADM1-AS1 expression as an independent prognostic factor for ccRCC (P <0.001, HR = 0.211, 95% CI = 0.088-0.504). In addition, we used small interfering RNA (siRNA) to evaluate the biological function of CADM1-AS1 in vitro. The results showed that CADM1-AS1 expression was positively associated with CADM1 mRNA expression in 786-O cells and ACHN cells. Functional experiments demonstrated markedly enhanced ability of growth and migration, and reduced apoptotic rate in CADM1-AS1 knocking down in 786-O cells. Conversely, overexpression of CADM1-AS1 showed a significant decrease in growth and migration, along with an increase in apoptotic rate in ACHN cells. In conclusion, our data demonstrated CADM1-AS1 is a new tumor suppressor in ccRCC which regulates cell proliferation, apoptosis and migration via the expression pattern of "CADM1-AS1/CADM1 mRNA gene pairs". CADM1-AS1 may be a potential biomarker and therapeutic target in patients with ccRCC.

Comprehensive evaluation of the cytotoxic T-lymphocyte antigen-4 gene polymorphisms in risk of bone sarcoma.

BACKGROUND: Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is a critical immunoregulatory molecule that attenuates the antitumor response by elevating the T-cell activation threshold, thus inducing occurrence of cancer. OBJECTIVE: Several studies have reported the associations of CTLA-4 polymorphisms and bone sarcoma, but the findings remain to be further verified due to incomplete and limited evidence. The purpose of this study was to reevaluate the associations via a comprehensive meta-analysis. METHODS: We searched Embase, Web of Knowledge, and PubMed and identified a total of four case-control studies fulfilling the inclusion criteria. Meta-analysis was conducted in all subjects without further stratified analyses. The associations were estimated by odds ratio (OR) along with 95% confidence interval (CI). RESULTS: Analysis showed a significant association for the +49G>A polymorphism. This association was more pronounced in the homozygous model (OR=1.85; 95% CI: 1.40, 2.46; p=0.998 for heterogeneity) and the recessive model (OR=1.85; 95% CI: 1.41, 2.42; p=0.959 for heterogeneity). The allele model also demonstrated statistical evidence, indicating a moderately increased risk of bone sarcoma in relation to the +49>A polymorphism (OR=1.21; 95% CI: 1.08, 1.36; p=0.996 for heterogeneity). Conversely, neither an increase or nor a decrease was observed in the genotypes of -318C>T polymorphism. CONCLUSIONS: Our meta-analysis provides evidence that support that the +49>A polymorphism, but not the -318C>T polymorphism, may be associated with elevated risk of bone sarcoma in Asians.

[Combined anterior and posterior surgeries for double column acetabular fracture].

OBJECTIVE: To explore the clinical effects and related factors of combined anterior and posterior surgeries in treatment of double column acetabular fracture. METHODS: From August 2007 to July 2009, 19 patients with double column acetabular fracture were treated. There were 13 males and 6 females, with a mean age of 39.6 years (ranged, 27 to 52 years). Among the patients, upper double column fracture was in 11 cases, lower double column fracture was in 8 cases and double column fracture involved sacroiliac joint in 1 case. The mean time from injury to operation was 5.8 days (ranged, 4 to 10 days). All patients were received combined anterior and posterior surgeries, reconstructed plate and fixed by screw. RESULTS: One patient was death, other patients were followed up from 12 to 18 months (with a mean time of 13.6 months). According to Harris standard, 9 cases got excellent results, 7 good cases and 2 fair. CONCLUSION: Combined anterior and posterior surgeries for double column acetabular fracture can get satisfactory effects.